Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL). Group 1 received vorinostat 400 mg daily, group 2 received vorinostat 300 mg twice daily for 3 days with 4 days...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Duvic, Madeleine, Talpur, Rakshandra, Ni, Xiao, Zhang, Chunlei, Hazarika, Parul, Kelly, Cecilia, Chiao, Judy H., Reilly, John F., Ricker, Justin L., Richon, Victoria M., Frankel, Stanley R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2007
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785068/
https://ncbi.nlm.nih.gov/pubmed/16960145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-025999
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky